FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

On February 22, 2017, the U.S. Food and Drug Administration (FDA) granted approval for the use of lenalidomide as maintenance therapy after autologous hematopoietic stem cell transplantation (auto‐HSCT) for patients with multiple myeloma. The approval was based on evidence from two randomized, blind...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Pulte, Elizabeth Dianne, Dmytrijuk, Andrew, Nie, Lei, Goldberg, Kirsten B., McKee, Amy E., Farrell, Ann T., Pazdur, Richard
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2018
Gaiak:
Regulatory Issues: FDA
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6067941/
https://ncbi.nlm.nih.gov/pubmed/29438096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0440
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak